Immutep (IMMP) has released an update.
Immutep has revealed promising results from the safety lead-in phase of its AIPAC-003 Phase II/III trial at the ESMO Breast Cancer 2024 Congress, including a complete response in a patient with metastatic breast cancer who had failed multiple therapies. The treatment combines Immutep’s soluble LAG-3 protein, eftilagimod alpha, with paclitaxel and has been shown to be safe and well-tolerated. Further efficacy and safety data from the study are anticipated in 2024.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
